Related Articles
Blood‑based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer‑risk stratification
Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia
Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies
Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone
Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis